Expression and prognostic significance of INSM1 compared with traditional neuroendocrine markers in mixed urothelial and small-cell carcinoma of the renal pelvis - Scorecard - MDSpire
Advertisement
Comparative Analysis of INSM1 Expression and Its Prognostic Value Against Conventional Neuroendocrine Markers in Mixed Urothelial and Small-Cell Carcinoma of the Renal Pelvis
Clinical Scorecard: Comparative Analysis of INSM1 Expression and Its Prognostic Value Against Conventional Neuroendocrine Markers in Mixed Urothelial and Small-Cell Carcinoma of the Renal Pelvis
At a Glance
Category
Detail
Condition
Mixed Urothelial Carcinoma and Small-Cell Carcinoma of the Renal Pelvis
Key Mechanisms
INSM1 as a nuclear transcription factor for neuroendocrine differentiation
Target Population
Patients with mixed renal pelvic UC/SmCC
Care Setting
Pathology and oncology
Key Highlights
INSM1 showed 96.3% sensitivity for the SmCC component.
INSM1 outperformed synaptophysin and chromogranin A in sensitivity.
Higher INSM1 H-score correlated with adverse overall survival.
Adjuvant chemotherapy was associated with reduced mortality risk.
CK7 and GATA3 were retained exclusively in the UC compartment.
Guideline-Based Recommendations
Diagnosis
Use INSM1 for identifying the SmCC component in mixed tumors.
Management
Consider adjuvant chemotherapy for improved survival outcomes.
Monitoring & Follow-up
Monitor INSM1 expression levels and overall survival in patients.
Risks
Advanced pT stage and nodal metastasis are associated with poorer outcomes.
Patient & Prescribing Data
27 patients with histologically confirmed mixed renal pelvic UC/SmCC.
INSM1 serves as a sensitive marker for neuroendocrine differentiation.
Clinical Best Practices
Accurate histopathological recognition of mixed UC/SmCC is critical.
Utilize a combination of INSM1, CK7, and GATA3 for diagnosis.
